Literature DB >> 2663232

Molecular genetics of Duchenne and Becker muscular dystrophy: emphasis on improved diagnosis.

L M Kunkel1, A H Beggs, E P Hoffman.   

Abstract

Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disorder affecting 1 in 3500 males. A less severe and less common form is Becker muscular dystrophy (BMD). Only recently has the basic defect in DMD and BMD been recognized: a region on the human X chromosome is disrupted by mutation. The primary transcript of the region was detected, and cDNA clones were isolated that encompassed the entire transcript. The sequence of the encoded protein was predicted from cDNA nucleotide sequence, portions of the protein were overexpressed in bacterial cells, and these peptides were used to generate immunoreagents against the DMD gene protein, dystrophin. The molecular genetic identification of this protein via analysis of mutations found in patients' material has led to a means of improved diagnosis of DMD/BMD in affected individuals and their family members. The severely affected DMD patients have little or no detectable dystrophin in their muscle, whereas BMD patients have nearly normal concentrations of an altered form of dystrophin; patients with all other neuromuscular diseases have normal dystrophin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663232

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

1.  Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.

Authors:  Sarah Forrest; Penny L Meloni; Francesco Muntoni; Jihee Kim; Sue Fletcher; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2010-12       Impact factor: 4.296

2.  Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis.

Authors:  Jinhong Zhu; Yong Li; Aiping Lu; Burhan Gharaibeh; Jianqun Ma; Tetsuo Kobayashi; Andres J Quintero; Johnny Huard
Journal:  Am J Pathol       Date:  2011-05-31       Impact factor: 4.307

3.  Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD).

Authors:  Camilla Brolin; Takehiko Shiraishi
Journal:  Artif DNA PNA XNA       Date:  2011-01

4.  Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.

Authors:  Anna Rufo; Andrea Del Fattore; Mattia Capulli; Francesco Carvello; Loredana De Pasquale; Serge Ferrari; Dominique Pierroz; Lucia Morandi; Michele De Simone; Nadia Rucci; Enrico Bertini; Maria Luisa Bianchi; Fabrizio De Benedetti; Anna Teti
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

5.  What Can We Learn From Clinical Trials of Exon Skipping for DMD?

Authors:  Qi-Long Lu; Sebahattin Cirak; Terence Partridge
Journal:  Mol Ther Nucleic Acids       Date:  2014-03-11       Impact factor: 10.183

Review 6.  Multiple Species Comparison of Cardiac Troponin T and Dystrophin: Unravelling the DNA behind Dilated Cardiomyopathy.

Authors:  Jennifer England; Siobhan Loughna; Catrin Sian Rutland
Journal:  J Cardiovasc Dev Dis       Date:  2017-07-07

7.  Regulation of the dystrophin-associated glycoprotein complex composition by the metabolic properties of muscle fibres.

Authors:  Saleh Omairi; Kwan-Leong Hau; Henry Collins-Hooper; Charlotte Scott; Sakthivel Vaiyapuri; Silvia Torelli; Federica Montanaro; Antonios Matsakas; Ketan Patel
Journal:  Sci Rep       Date:  2019-02-26       Impact factor: 4.379

8.  Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice.

Authors:  Yusuke Echigoya; Yoshitsugu Aoki; Bailey Miskew; Dharminder Panesar; Aleksander Touznik; Tetsuya Nagata; Jun Tanihata; Akinori Nakamura; Kanneboyina Nagaraju; Toshifumi Yokota
Journal:  Mol Ther Nucleic Acids       Date:  2015-02-03       Impact factor: 10.183

9.  A well-tolerated core needle muscle biopsy process suitable for children and adults.

Authors:  Florian Barthelemy; Jeremy D Woods; Shirley Nieves-Rodriguez; Emilie D Douine; Richard Wang; Jonathan Wanagat; M Carrie Miceli; Stanley F Nelson
Journal:  Muscle Nerve       Date:  2020-09-20       Impact factor: 3.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.